USPTO serial 87771608
FARON
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 6, 2021
- Examiner
- FERRELL, LUCY K
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with FARON?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $299*
Plus Government fees of $325
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Mark E. Olds
Mark E. Olds Muncy, Geissler, Olds & Lowe, P.C.4000 Legato Road Suite 310Fairfax, VA 22033UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Pharmaceutical research and development; Development of pharmaceutical preparations and medicines; Conducting clinical trials for others; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Medical research; all the aforementioned services relating to pharmaceutical preparations for treatment and prevention of ischemic conditions, inflammations and organ damages resulting from tissue traumas, reperfusion injuries, cancer, cancer metastasis, inflammatory conditions and allergic conditions, or to pharmaceutical preparations for treatment and prevention of multiorgan failure, acute lung injury and acute respiratory distress syndrome in adults, adolescents, children, infants and neonates, or to medical and veterinary preparations to prevent inflammations and cancer growth and spread, or to pharmaceutical preparations for the treatment of cancer, or to tumor suppressing agents, or to antineoplastics, or to anti-cancer preparations, or to compounds for treating cancer, or to antibodies for medical use to treat inflammation and cancer growth and spread, or to adjuvants for medical purposes, or to vaccine adjuvants | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 6, 2026 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Mar 18, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 18, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 18, 2022 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Mar 18, 2022 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Mar 18, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 18, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 18, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jul 6, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 20, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 20, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 31, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 16, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 12, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 12, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 10, 2021 | ALIE | ASSIGNED TO LIE | — |
| Dec 8, 2020 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Jul 28, 2020 | LOPR | LETTER OF PROTEST EVIDENCE REVIEWED-NO FURTHER ACTION TAKEN | — |
| Jul 27, 2020 | LOPT | LETTER OF PROTEST EVIDENCE FORWARDED | — |
| Jun 10, 2020 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Jun 10, 2020 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Jun 10, 2020 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Dec 10, 2019 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Jun 10, 2019 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Dec 10, 2018 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| May 22, 2018 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| May 22, 2018 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| May 22, 2018 | CNSL | SUSPENSION LETTER WRITTEN | — |
| May 21, 2018 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 21, 2018 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 21, 2018 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 21, 2018 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 9, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 7, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 30, 2018 | NWAP | NEW APPLICATION ENTERED | — |